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Abstract: Dementia has been shown to be associated with
agonistic autoantibodies. The deleterious action of
autoantibodies on the α1-adrenergic receptor for brain
vasculature has been demonstrated in animal studies. In
the current study, 169 patients with dementia were
screened for the presence of agonistic autoantibodies.
47% of patients suffering from mild to moderate
Alzheimer’s disease and/or vascular dementia carried these
autoantibodies. Eight patients positive for autoantibodies
underwent immunoadsorption. Patients treated on four
consecutive days were subsequently negative for
autoantibodies and displayed stabilization of cognitive
and mental condition during 12–18 months’ follow-up. In
patients treated for 2–3 days, autoantibodies were reduced
by only 78%. They suffered a rebound of autoantibodies
during follow-up, benefited from immunoadsorption too,
but their mental parameters worsened. We provide first
data on the clinical relevance of agonistic autoantibodies
in dementia and show that immunoadsorption is safe and
efficient in removing autoantibodies with overall benefits
for patients. Key Words: Autoantibodies, Brain vascu-
lature, Dementia, Immunoadsorption, α1-Adrenergic
receptor.
Dementia is a widespread progressive disease with
devastating effects on the patient and caregivers and,
due to demographic changes, presents a massively
growing economic burden as well. Currently, more
than 1.4 million people in Germany aged 65 years
and older suffer from dementia, with two-thirds of
those having Alzheimer’s disease (AD) – with an
anticipated incidence of 300000 patients per year (1).
Alzheimer’s disease is the most common form of
dementia, followed by vascular dementia (VaD)
caused by lesions in blood vessels supplying the
brain. A significant number of patients with
dementia suffer from a mixed-type dementia (2).
AD pathology is characterized by deposits of β-
amyloid containing senile plaques and cerebral
tangles containing phospho-tau. Beta-amyloid has
long been thought to be a promising therapeutic
target. However, several clinical approaches to
remove and/or decrease the synthesis of β-amyloid
failed to yield a significant benefit (3–5). There are
multiple causes of dementia. Lifestyle, genetic risk
factors, and vascular impairments have been
acknowledged as playing important roles (6–8).
Lesions of blood vessels in particular are thought
to play an important role in AD pathology as well.
Vascular risk factors that have been shown to
increase the risk for AD may act both independently
and by amplifying each other. These include
diabetes, hypertension, obesity, and high blood-
cholesterol levels (9). Interestingly, in several clinical
studies focusing on the effect of treating hypertension
and examining dementia as a secondary outcome,
decreased incidence of dementia (10) or cognitive
decline (11,12) has been observed.
Agonistic autoantibodies (agAAB) directed against
G-protein-coupled receptors (GPCR) are increas-
ingly discussed as modulators of the pathology and
outcome of diseases with vascular complications,
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such as dilated cardiomyopathy (13,14), hypertension
(14,15), type-2 diabetes mellitus (16), dementia
(17,18), thromboangiitis obliterans (19), preeclampsia
(20,21), and humoral-mediated kidney transplant
rejection (22). In these instances, agAAB directed
against the α1-adrenergic receptor (15,18), the β1-
adrenergic receptor (13,14), the β2-adrenergic re-
ceptor (17), the endothelin A receptor (14,19) and
the angiotensin-1 receptor (20,22) have been de-
scribed. The pathogenic potential of circulating
agAAB has already been demonstrated in animal
models as well as in clinical studies (13,15,21,23).
The pathogenic effect of agAAB (fulfilling Koch’s
criteria) has been demonstrated in rat models for the
β1-adrenergic receptor autoantibodies in dilated
cardiomyopathy (13) and for the α1-adrenergic
receptor (18).
Elimination of IgG by immunoadsorption is highly
effective in removing agAAB (14,19). Several
smaller case studies have revealed improvement
in cardiac function, i.e. improved left ventricular
ejection fraction, natriuretic peptide levels, and
hemodynamic conditions, with a long-lasting effect
on the symptoms of heart failure by removal of
agAAB through immunoadsorption (14).
The potential for agAAB to act against the α1-
adrenergic receptor (α1-AR) and thereby cause
damage in the macro- and microvasculature of the
brain has been shown in rats for aorta and
mesenteric arteries (23) and arteries of the brain
(18). AgAAB acting against the α1-AR cause a
significant reduction of blood flow in certain parts
of the brain, such as the hippocampus, and a
significant decrease of vessel density in parts of
the cortex (24). These findings imply a general
significance of the α1-AR-agAAB interaction in
the pathogenesis and progression of diseases
having a strong vascular component such as
dementia.
In an earlier study that investigated the incidence
of agAAB against the α1-AR in patients suffering
from AD combined with VaD (AD/VaD), agAAB
were detected in approximately 50% of the patients
(17). We hypothesized that agAAB against the α1-
AR play a substantial role in the pathogenesis of
AD/VaD.
In this study, immunoadsorption was used as a
novel therapeutic approach for patients with
dementia. To our knowledge, there have been no
studies on the benefit of immunoadsorption in
patients with AD/VaD to date. In an exploratory
study, patients with mild to moderate dementia and
positive for agAAB acting against α1-AR received
immunoadsorption. Over a follow-up period of up
to 18 months, the agAAB level and cognitive
changes were observed.
PATIENTS AND METHODS
Patients with AD/VaD were screened for the
presence of agAAB. AgAAB were determined using
a peptide based ELISA as described in (17). The cut-
off value of the ELISAwas defined using samples of
patients who were negative for agAAB in the
functional bioassay (17).
A random sample of patients with mild to
moderate AD/VaD, affirmed by Mini-Mental State
Examination score (MMSE; ≥18–26), and positive
for α1-AR-agAAB were selected for immuno-
adsorption with the intention of removing agAAB
from their blood circulation. These patients had to
meet the following two additional criteria: capacity
to provide consent and stable pharmacological
antidementive treatment for a period of at least three
months. Exclusion criteria were an age >90 years,
hemodialysis, severe cardiac diseases (infarction,
insufficient cardio capacity, cardiac bypasses, etc.),
cerebral bleeding, immunodeficiency, and oncologic
diseases.
Cognitive and noncognitive testing was performed
prior to immunoadsorption and at 3, 6, and 12–18
months after immunoadsorption. The following tests
were used in the diagnosis of AD/VaD and have
proven to be reliable tools for initial evaluation of a
patient as well as for monitoring the progress of
cognitive deficits: Mini-Mental State Examination
(MMSE), Alzheimer’s Disease Assessment scale
(ADAS-cog and -noncog), Bayer Activities of Daily
Living (Bayer-ADL), Clinical Global Impression
Scale (CGI), Geriatric Depression Scale (GDS),
and Short Cognitive Performance Test (Syndrom-
Kurz-Test, SKT) (Table 1).
Immunoadsorption was performed over a period
of four consecutive days (centrifuge for blood
cell/plasma separation: COM.TEC, Fresenius Kabi,
Bad Homburg, Germany; immunoadsorption system:
ADAsorb, medicap GmbH, Ullrichstein, Germany;
adsorber: Immunosorba, Fresenius Medical
Deutschland GmbH, Bad Homburg, Germany).
The Fresenius Immunosorba is based on protein A
and selectively removes all immunoglobulins without
affecting other serum proteins. Patients were treated
as outpatients. One day of immunoadsorption was
made up of several cycles. The daily processed
plasma volume was in the range of 2.0–2.5-fold. After
the last cycle of immunoadsorption, the IgG level
was <15% and human immunoglobulin (>98%
IgG) was substituted. During immunoadsorption
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and IgG substitution, patients were monitored by
measuring blood pressure and heart rate under the
constant supervision of a physician and a specially
trained nurse. The study was conducted in
compliance with the Declaration of Helsinki and
approved by the ethical review committee of the
Charité - Universitätsmedizin Berlin (EA1/058/10).
Blood samples were regularly taken before the
first and after the last cycle of immunoadsorption
and whenever needed. AgAAB analyses were
performed retrospectively.
RESULTS
A cohort of 169 patients with dementia diagnosed as
being at different stages was screened for the
presence of agAAB using the standardized in-house
ELISA. 85 of the patients examined (>50%) were
positive for agAAB. 74 (>43%) out of 169 patients
tested positive for α1-AR-agAAB and 54 (73%) of
these patients also harbored β2-AR-agAAB.
AgAAB acting against the α1-AR or β2-AR only
occurred in 20 and 11 patients, respectively. Focusing
only on mild to moderate AD/VaD (MMSE 20-26),
we found the incidence to be similarly distributed in
the resulting 66 patients. 36 (>54%) patients with
mild to moderate AD/VaD were positive for agAAB
and 31 (47%) of them were harboring agAAB acting
against α1-AR. Of these, 22 (71%) were positive for
both α1-AR-agAAB and β2-AR-agAAB. Only five
patients showed agAAB acting solely against the
β2-AR. However, the pathological relevance of β2-
AR-agAAB is still unclear, and there are no animal
or clinical studies available that have tackled this
problem. Therefore, patients carrying only β2-AR-
agAAB were not included. Thus, 31 patients with
α1-AR-agAAB were considered to be potential
candidates for immunoadsorption.
Eight patients meeting the inclusion criteria
mentioned above were selected for immuno-
adsorption and gave their consent for this treatment.
Three individuals were female, five were male. Mean
age was 66.8 ±2.9 years. All patients were positive for
agAAB against the α1-AR and five also harbored
β2-AR-agAAB.
Immunoadsorption treatment over the 4 day course
carried out according to the protocol (Group 1)
effectively removed 96 ±12% of α1-agAAB from the
sera gradually (Fig. 1a). Due to the outpatient
treatment regimen, permanent catheterization of the
jugular vein was not feasible. The repeated daily
puncture caused access to the vein of four patients to
deteriorate. Therefore, these patients could only be
treated for two to three consecutive days (Group 2).
The shortening of treatment time led to incomplete
removal of agAAB (78 ±10%, Fig. 1b). There were
no safety or tolerability problems with the
immunoadsorption in any of the patients. Follow-up
examination of the agAAB status after 3, 6, and
12–18 months showed no reoccurrence of agAAB in
Group 1 (only in one patient did α1-AR-agAAB
reappear after 12 months), whereas agAAB
reappeared after 3 months in two patients and after 6
months in three patients of Group 2.
To evaluate cognitive changes after removal of
agAAB, several cognitive and noncognitive tests
were performed prior to immunoadsorption and at
3, 6, and 12–18 months after immunoadsorption.
These were MMSE, ADAS-cog and -noncog,
Bayer-ADL, CGI, GDS, and SKT.
All eight patients treated showed a stable
condition in different behavioral tests of daily living
skills during the follow-up period without dramatic
changes in the results of important tests (e.g. Bayer-
ADL, CGI, GDS, SKT) (Table 2). This correlates
with personal communications from relatives shortly
after immunoadsorption. They reported an overall








Mini-Mental State Examination diagnoses dementia and assesses its progression
and severity
30 points 0 points 26–30 points
Alzheimer’s Disease Assessment scale – cognitive assessment of cognitive
functions (language and memory)
0 points 70 points 0–5 points
Alzheimer’s Disease Assessment scale – noncognitive assessment of noncognitive
functions ( mood and behaviour)
0 points 50 points 0–5 points
Bayer Activities of Daily Living assessment of impairments to performance of daily
activities
1 points 10 points 1–2 points
Clinical Global Impression Scale clinician’s view of the patient’s global functioning 1 point 7 points 1 point
Geriatric Depression Scale assessment of depression in the elderly 0 points 15 points 0–5 points
Short Cognitive Performance Test assessment of memory and attention deficit in
dementia patients
0 points 27 points 0–4 points
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positive feeling about the mental health and behavior
of the patients. Of course, the precise changes are
very different for each individual, but the patients’
relatives pointed out that their condition had
immensely improved.
Interestingly, MMSE remained stable in Group 1
and showed the same results prior to and 12–18
months after immunoadsorption, while MMSE in
Group 2 declined by 5.25 points (Fig. 2a, Table 2).
This is similar to changes in untreated patients
(MMSE decline by about 2–4 points annually, 25).
ADAS-cog and ADAS-noncog changed over the
observed follow-up period in Group 1 by 2.00 ±1.73
points and by 2.17 ±2.89 points, respectively, and in
Group 2 by 1.88 ±5.18 points and by 2.00 ±1.58 points,
respectively (Fig. 2b and c). Cognitive decline of
dementia patients without proper medication changes
over the same time period by 7–11 points (25).
Immunoadsorption led to long-lasting elimination
of agAAB from the blood circulation only in patients
treated for 4 days. Cognitive development in these
patients stabilized and daily living skills clearly
improved.
DISCUSSION
AgAAB directed against GPCR are increasingly
recognized as a significant factor in widespread
diseases. In particular, agAAB directed at the α1-AR
were found to be characteristic of various pathologies
having in common the involvement of vascular
impairment as a necessary cause and in the pro-
gression of the disease. These include different forms
of hypertension, type-2 diabetes, thromboangiitis
obliterans and dementia (15–17,19). Alzheimer’s
disease, the predominant form of dementia, continues
a b
FIG. 1. Detection of agonistic autoantibodies against α1-adrenoceptors (α1-AR-agAAB) in sera of patients with dementia before, during
and after immunoadsorption for 4 days (a) and for 2–3 days (b). Serum was collected on consecutive days prior and after immunoadsorption
and at 3, 6, and 12–18 months after as follow-up. Peptide specific binding of α1-AR-agAAB was analyzed by ELISA and calculated as
percentage change of the initial value. Values are means ± SEM of (N) analyzed patients.
TABLE 2. Cognitive data from the study groups. Group 1 treated 4 consecutive days, Group 2 treated 2–3 days
Δ versus before immunoadsorption (IA)
Before IA 3 months 6 months 12–18 months
MEAN SEM N MEAN SEM N MEAN SEM N MEAN SEM N
Group 1
MMSE 22.25 1.31 4 0.00 1.29 4 –1.25 1.18 4 0.00 1.73 3
ADAS-cog 21.75 5.25 4 –0.25 1.31 4 –0.50 2.02 4 2.00 1.73 3
ADAS-noncog 3.25 0.25 4 1.50 2.02 4 1.75 3.25 4 2.17 2.89 3
BayerADL 4.52 0.83 4 –0.35 0.41 4 –0.13 0.44 4 0.45 0.50 3
CGI 3.50 0.29 4 0.25 0.48 4 0.50 0.50 4 1.33 0.33 3
GDS 3.00 1.08 4 1.25 0.85 4 1.50 1.55 4 –0.67 1.20 3
SKT 13.50 3.66 4 1.25 0.85 4 1.75 1.11 4 3.67 1.20 3
Group 2
MMSE 22.00 1.83 4 0.00 0.71 4 –1.75 1.18 4 –5.25 4.61 4
ADAS-cog 23.25 4.37 4 –0.50 3.66 4 –4.00 2.68 4 1.88 5.18 4
ADAS-noncog 3.25 0.85 4 0.25 1.11 4 0.50 1.04 4 2.00 1.58 4
BayerADL 4.05 0.40 4 0.41 0.48 4 0.68 0.27 4 1.56 0.37 4
CGI 3.50 0.29 4 0.00 0.00 4 –1.00 1.47 4 1.50 0.65 4
GDS 3.75 0.63 4 0.25 0.85 4 0.50 0.29 4 –0.25 0.63 4
SKT 8.25 1.11 4 –2.75 1.11 4 0.75 1.65 4 3.00 3.74 4
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to increase as a health problem of aging. Despite
tremendous efforts to determine the cause of
Alzheimer’s disease or slow its progression, no
successful treatment has been established up to now.
Here we report on the prevalence of agAAB
directed against the α1-AR in a cohort of patients
suffering from dementia, mostly of the Alzheimer’s
type, and provide the first data on eliminating
agAAB from the blood circulation of dementia
patients through immunoadsorption. To our
knowledge, immunoadsorption has not been applied
as a therapeutic strategy for patients with dementia
before. Immunoadsorption has proven to be a safe
and efficient procedure in antibody-mediated dilated
cardiomyopathy accompanied by agAAB against the
β1-AR (14). After removal of β1-AR-agAAB,
cardiac performance of patients improved
significantly and persistently, in some cases obviating
the need for heart transplantation (14).
The present study used immunoadsorption to
remove α1-AR-agAAB quantitatively from dementia
patients’ blood circulation. Immunoadsorption was to
be performed on 4 consecutive days according to the
study protocol. Due to outpatient treatment
arrangements, repeated daily puncture of the vein
was necessary. Access to the vein deteriorated so
much in a group of patients (retrospectively
termed Group 2), that they could only be treated
for 2–3 consecutive days. However, this allowed us
to gather additional valuable information on the
time schedule that is critical for the complete
removal of agAAB from the blood circulation by
comparing these patients with the group treated
for 4 days. The significant reappearance of
agAAB during the follow-up in patients treated
for 2–3 days correlates with the tendency for a
decline of the MMSE status, whereas the level
of the agAAB in the patient group treated for
four days appeared to be stabilized. Patients with
the 4-day apheresis remained negative for agAAB
with one exception.
The availability of agAAB for detection is
restricted to the fraction of circulating antibodies.
However, the pathologically active agAAB are those
bound to the α1-AR. In vivo data on time constants
of agAAB binding to the receptor and their
dissociation from the receptor are not available. This
also suggests that estimations of total serum
immunoglobulins do not reflect the present agAAB
situation of the patient, especially regarding the
receptors in their physiologic milieu. In vitro data
on the tight and durable association of antibodies
a
b c
FIG. 2. Evaluation of Mini-Mental State Examination score (MMSE) (a) and Alzheimer’s Disease Assessment Scale (ADAS-cog and -
noncog) (b, c) in patients with mild to moderate Alzheimer’s and/or vascular dementia before and after immunoadsorption of 4 days
(Group 1, filled triangle) and 2–3 days (Group 2, open squares). Cognitive tests were performed before and 3, 6, and 12–18 months after
immunoadsorption under controlled clinical conditions. Data are given as differences to the estimates obtained prior to immunoadsorption.
Means were calculated ± SEM of N= 4 (Group 1) and N= 2–4 (Group 2) analyzed patients. The averaged trend of cognitive progression in
untreated dementia patients is indicated as a dotted line (25).
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with their target sites revealed EC50 (half maximal
effective antigen concentration) values in the low
nanomolar range (15,17). It may be concluded that
immunoadsorption for less than 4 days is not
sufficient to remove agAAB from their binding
compartments. Thus, the present study proves that
immunoadsorption is a safe and effective procedure
to relieve dementia patients persistently of α1-AR-
agAAB. The data suggest immunoadsorption should
be performed for five consecutive days to ensure the
complete removal of the non-circulating receptor-
bound fractions of agAAB as well. Moreover, we
recommend hospitalization of the patient to avoid
possible problems arising from repetitive vein
puncture.
Dementia is a progressive disease characterized by
cognitive decline and mostly irreversible pathological
changes in the brain. Therefore, the complete cure of
this disease may be an unrealistic goal at present. To
stop or at least to slow the progression of dementia
accompanied by stabilization of the cognitive
situation of the patient represents a significant
therapeutic success. Follow-up examinations of
patients who received 4-day immunoadsorption
demonstrated the absence of the α1-AR-agAAB up
to 18 months after immunoadsorption and stabilized
cognitive performance as verified by stable results
in cognitive tests such as ADAS and MMSE. Some
aspects of abilities needed in daily life and subjective
well-being even appeared to improve. Thus, the
removal of α1-AR-agAAB from the blood cir-
culation of dementia patients by immunoadsorption
produced an impressive therapeutic success that has
not even been approached by current pharmaco-
logical treatments (3–5). The data presented
underscore the importance of a sufficient number of
consecutive days of immunoadsorption for the
complete removal of α1-AR-agAAB to ensure their
long-lasting absence and to prevent a recurrence of
the autoantibody.
In this context it should be noted that α1-AR-
agAAB are also involved in hypertension (15). The
elimination of α1-AR-agAAB from dementia
patients with hypertension may require adjustment
of their antihypertensive medication.
The present observations demonstrate for the first
time evidence of the pathological effect of agAAB
on the α1-AR in patients suffering from dementia.
The damaging action of this type of agAAB on the
vasculature has been demonstrated in animal studies
for peripheral vessels and for macro- and
microvessels of the brain (18,23). In addition to
direct damage to and destruction of cerebral blood
vessels, antibody-treated animals showed signs of
neurodegeneration with increased dilation of
Virchow-Robin spaces (unpublished data). This
indicates that α1-AR-agAAB negatively affect both
the blood supply of neuronal tissue and the drainage
of cerebral fluids. Reduced drainage may attenuate
the clearance of β-amyloid species from the vicinity
of neuronal cells and constitute another mechanism
by which α1-AR-agAAB contributes to the
progression of the disease. The cohort studied
consisted predominantly of patients suffering from
dementia of the Alzheimer’s and vascular type, with
about 44% of patients being positive for α1-AR-
agAAB. Given that the presence of α1-AR-agAAB
represents a general risk for vascular impairments
and neurodegeneration, these autoantibodies are
likely to be of clinical relevance in other forms of
dementia, such as frontotemporal dementia and
Lewy body dementia.
However, on the negative side, while
immunoadsorption achieves rapid and safe
elimination of agAAB, it is costly and involved.
Plasmapheresis is a less expensive procedure.
However, the substitution of the patients’ plasma
with plasma from donors entails risk of distributing
pathogens, such as various autoantibodies not
identified by standard diagnostics used for
certification of donor plasma. The interaction of
agAAB with their target receptors might also be
reduced by receptor antagonists. Most antagonists
of relevant receptors are in clinical use for other
indications. Antagonists of the α1-AR are used to
treat hypertension and prostate hyperplasia. To
achieve a significant effect of receptor antagonists
on agAAB circulating in patients requires greater
orders of magnitude of time compared to the
removal of agAAB through apheresis (unpublished
observation). Considering the relatively rapid
decline in cognition of dementia patients, the
receptor antagonist approach would suffer from this
crucial drawback. Moreover, receptor antagonists
act systemically, thereby affecting various organs
carrying the respective receptor type.
CONCLUSION
In summary, we have demonstrated for the first time
the therapeutic efficacy of immunoadsorption for
treating dementia in a random sample of α1-AR-
agAAB positive patients. The data confirm the
neuropathogenic action of α1-AR-agAAB in humans
as previously demonstrated in animal models (18).
AgAAB-mediated cerebrovascular impairment may
be a missing link in the pathogenesis of AD/VaD.
In light of the lack of effective therapies for
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dementia, immunoadsorption represents a promising
treatment approach for at least agAAB-positive
patients. In respect to AD pathogenesis, parallel
chronic pathological cerebrovascular mechanisms
may be modified by immunoadsorption, resulting in
improved cerebrovascular blood circulation as well
as regional clearance. It may be an ad hoc treatment
tool to interrupt the vascular contribution to
cognitive impairments. Long-lasting cognitive
stabilization after a single 5-day treatment interval
may be a pivotal advantage, considering the poor
efficacy of current drug therapy. Larger controlled
studies are needed to verify the present observations,
optimize the treatment protocol, and evaluate
immunoadsorption for clinical use.
There are limitations to this explorative study that
should be stated. Due to the nature of the set-up
and operation of specialized hospitals such as the
EGZB, it was not possible to establish a control
group of agAAB-positive patients not treated by
immunoapheresis. The outpatients are examined only
once in this hospital and then transferred back to their
family doctor for care. The progressive worsening of
dementia patients’ cognitive and mental condition is
beyond dispute and well documented by established
tests. However, the averaged progression trend, used
here for illustration, is inappropriate for control.
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